Skip to main content
Vivo Bio tech Ltd. logo

Vivo Bio tech Ltd. — Investor Relations & Filings

Ticker · 511509 ISIN · INE380K01017 LEI · 98450079E4M2CR80D882 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 445 across all filing types
Latest filing 2026-06-02 Earnings Release
Country IN India
Listing BSE.NS 511509

About Vivo Bio tech Ltd.

http://www.vivobio.com/

Vivo Bio Tech Ltd. is a preclinical Contract Research Organization (CRO) providing comprehensive drug discovery and development services. The company specializes in conducting in vivo preclinical studies, including toxicology, pharmacology, and pharmacokinetic evaluations. It operates advanced facilities for the breeding and distribution of Specific Pathogen Free (SPF) laboratory animal models, maintained through strategic partnerships with global leaders like Taconic Biosciences. Vivo Bio Tech offers regulatory-compliant services such as safety assessment, efficacy testing, and specialized research models to support pharmaceutical and biotechnology sectors. Its operations are characterized by adherence to Good Laboratory Practice (GLP) standards and AAALAC accreditation, ensuring high-quality data for global regulatory submissions.

Recent filings

Filing Released Lang Actions
Newspaper publication for the Audited Financial Results for the Quarter and Year ended March 31, 2026.
Earnings Release Classification · 87% confidence The document is a SEBI Reg.30 filing enclosing the newspaper advertisements of the company’s audited financial results for the quarter and year ended March 31, 2026. Although it provides summary tables of total income, profit, EPS etc., it is a high‐level release of quarterly/period results rather than a full interim report. This matches the “Earnings Release” definition (initial announcement of quarterly financial results, key highlights only).
2026-06-02 English
please fine enclosed
Earnings Release Classification · 88% confidence The document is a formal stock-exchange filing under SEBI LODR, announcing the audited standalone and consolidated financial results for Q4 and the full year ended March 31, 2026. It includes detailed P&L and cash flow tables but is structured as an exchange announcement of results following a board meeting. This matches an Earnings Release rather than a full annual report or interim narrative. Hence, classify as ER. FY 2026
2026-05-30 English
please find enclosed
Interim / Quarterly Report Classification · 88% confidence The document is the formal outcome of a board meeting under SEBI LODR Regulations 30/33 announcing the audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2026. It includes detailed financial statements (income statement, cash flow, standalone and consolidated results) rather than just key highlights. This matches the definition for an Interim/Quarterly Report (IR), which requires actual financial data for a period shorter than a full fiscal year. FY 2026
2026-05-30 English
please find enclosed outcome of the Board Meeting
Interim / Quarterly Report Classification · 85% confidence The document is a formal announcement to the stock exchange under SEBI Listing Obligations (Regulations 30/33) detailing the audited standalone and consolidated financial results for the fourth quarter and full year ended March 31, 2026, complete with P&L, cash flow statements, and balance sheet line items. It is more than just key highlights (ruling out an ER) and is not a full annual report (10-K) but a comprehensive interim/quarterly financial report containing substantive data. Therefore it should be classified as an Interim / Quarterly Report. FY 2026
2026-05-30 English
Vivo Bio Tech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve 1. To consider and approve ....
Regulatory Filings Classification · 85% confidence The document is a formal announcement to the stock exchange under SEBI Listing Regulations informing about the postponement and rescheduling of a Board of Directors meeting. It does not present financial results itself, nor is it a management change notice, call transcript, or any other specific report. There is no specific category for board meeting notices, so this falls into the general regulatory announcement bucket. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-29 English
Vivo Bio Tech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve 1. To consider and approve the ....
Regulatory Filings Classification · 82% confidence The document is an intimation of the date of a Board of Directors meeting under SEBI LODR Regulation 29. It does not present financial results or substantive content itself but merely notifies the company’s regulator and exchange of the meeting date and agenda. It is not a full annual or interim report, nor an earnings release, call transcript, or change in management. Therefore it falls under the general regulatory announcements category (fallback).
2026-05-25 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.